These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
27. Androgen receptor antagonists for prostate cancer therapy. Helsen C; Van den Broeck T; Voet A; Prekovic S; Van Poppel H; Joniau S; Claessens F Endocr Relat Cancer; 2014 Aug; 21(4):T105-18. PubMed ID: 24639562 [TBL] [Abstract][Full Text] [Related]
28. [AUO study AP 59/10: first-line therapy of castration-resistant prostate cancer]. Rexer H Urologe A; 2011 Jun; 50(6):722-4. PubMed ID: 21584827 [No Abstract] [Full Text] [Related]
29. [Abiraterone acetate (AA): current guidelines of prescription of abiraterone]. Boissier E; Loriot Y; Vignot S; Massard C Bull Cancer; 2014 Apr; 101(4):388-93. PubMed ID: 24793632 [TBL] [Abstract][Full Text] [Related]
30. Treatment decisions for metastatic castration-resistant prostate cancer progressing after docetaxel chemotherapy: the role of cabazitaxel in the continuum of care. Heidenreich A; Pfister D Eur Urol; 2012 Dec; 62(6):1201-4. PubMed ID: 22964168 [No Abstract] [Full Text] [Related]
31. Abiraterone acetate: a novel drug for castration-resistant prostate carcinoma. Nandha R J Postgrad Med; 2012; 58(3):203-6. PubMed ID: 23023354 [TBL] [Abstract][Full Text] [Related]
32. Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial. Logothetis CJ; Basch E; Molina A; Fizazi K; North SA; Chi KN; Jones RJ; Goodman OB; Mainwaring PN; Sternberg CN; Efstathiou E; Gagnon DD; Rothman M; Hao Y; Liu CS; Kheoh TS; Haqq CM; Scher HI; de Bono JS Lancet Oncol; 2012 Dec; 13(12):1210-7. PubMed ID: 23142059 [TBL] [Abstract][Full Text] [Related]
33. Targeting continued androgen receptor signaling in prostate cancer. Massard C; Fizazi K Clin Cancer Res; 2011 Jun; 17(12):3876-83. PubMed ID: 21680543 [TBL] [Abstract][Full Text] [Related]
38. Cabazitaxel: a new drug for metastatic prostate cancer. Bilusic M; Dahut WL Asian J Androl; 2011 Mar; 13(2):185-6. PubMed ID: 21151153 [No Abstract] [Full Text] [Related]
39. Zibotentan for the treatment of castrate-resistant prostate cancer. Shepard DR; Dreicer R Expert Opin Investig Drugs; 2010 Jul; 19(7):899-908. PubMed ID: 20497097 [TBL] [Abstract][Full Text] [Related]
40. Cabazitaxel for the treatment of prostate cancer. Michielsen DP; Braeckman JG; Denis L Expert Opin Pharmacother; 2011 Apr; 12(6):977-82. PubMed ID: 21406025 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]